Loading
Luye Pharma Group Ltd. is a listed company. Its directors and officers file their transactions with HKEX. 1 insider has disclosed 2 filings since 18 October 2025.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Over the last twelve months, not one insider purchase of Luye Pharma Group Ltd. stock was filed.
This summary is built from HKEX disclosures alone and does not predict where the share price will go.
Analysts rate Luye Pharma Group Ltd. Buy (bullish), based on 2 analysts. Average price target: HK$2.82.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
2 of 2 declarations
Luye Pharma Group Ltd. is a pharmaceutical company focused on the development and commercialization of innovative drugs. It specializes in treatments for serious diseases and specific medical conditions.